Takara Bio Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
31

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“Takaro Bio - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Takaro Bio. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Takaro Bio - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Takara Bio

  1.1 Business Overview

  1.2 Takara Bio Pipeline Overview

 

2. Takara Bio Cancer Drugs in Preclinical Phase

  2.1 TCR-Gene-Transduced Autologous Lymphocytes - Takara Bio

 

3. Takara Bio Cancer Drugs in Clinical

  3.1 Midostaurin Companion Diagnostic - Invivoscribe/Novartis

  3.2 T-Cell Adoptive Immunotherapy – Cellectis

 

4. Takara Bio Cancer Drugs in Phase-I

  4.1 Natural killer Cell Therapy - Takara Bio

  4.2 TBI 1201

  4.3 WT1 TCR-Transduced T-Cell Therapy - Takara Bio

  4.4 Retronectin-Induced T Cell Therapy - Takara Bio

 

5. Takara Bio Cancer Drugs in Phase-I/II

  5.1 CD19 Chimeric Antigen Receptor T Cell Therapy - Takara Bio

 

6. Takara Bio Cancer Drugs in Phase-II

  6.1 TBI 1301

  6.2 HF 10

 

7. Takara Bio Cancer Drugs in Registered

  7.1 Thymidine kinase Cell Therapy – MolMed

 

8. No Development Reported in Cancer Drugs in Clinical Pipeline

  8.1 Cancer Vaccine - MolMed/San Raffaele Scientific Institute

 

9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 Gusperimus

Figure 1-1: Takara Bio Cancer Pipeline by Phase (%)

Figure 1-2: Takara Bio Cancer Pipeline by Phase (Number)

Figure 1-3: Takara Bio Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Takara Bio Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)